A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors

ConclusionsThe combination of these AKT and mTOR inhibitors was safe and feasible in patients with recurrent/refractory pediatric solid tumors.

Source: Pediatric Blood and Cancer - December 29, 2016 Category: Cancer & Oncology Authors: Oren J. Becher, Stephen W. Gilheeney, Yasmin Khakoo, David C. Lyden, Sofia Haque, Kevin C. Braganca, Jill M. Kolesar, Jason T. Huse, Shakeel Modak, Leonard H. Wexler, Kim Kramer, Ivan Spasojevic, Ira J. Dunkel Tags: Research Article Source Type: research